Literature DB >> 11929755

Autoimmunity in human primary immunodeficiency diseases.

Peter D Arkwright1, Mario Abinun, Andrew J Cant.   

Abstract

Human primary immunodeficiency diseases are experiments of nature characterized by an increased susceptibility to infection. In many cases, they are also associated with troublesome and sometimes life-threatening autoimmune complications. In the past few years, great strides have been made in understanding the molecular basis of primary immunodeficiencies, and this had led to more focused and successful treatment. This review has 3 aims: (1) to highlight the variety of autoimmune phenomena associated with human primary immunodeficiency diseases; (2) to explore how primary immunodeficiencies predispose patients to autoimmune phenomena triggered by opportunistic infections; and (3) to consider the rationale for the current treatment strategies for autoimmune phenomena, specifically in relation to primary immunodeficiency diseases. Reviewing recent advances in our understanding of the small subgroup of patients with defined causes for their autoimmunity may lead to the development of more effective treatment strategies for idiopathic human autoimmune diseases.

Entities:  

Mesh:

Year:  2002        PMID: 11929755     DOI: 10.1182/blood.v99.8.2694

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  Arthritogenic self-reactive CD4+ T cells acquire an FR4hiCD73hi anergic state in the presence of Foxp3+ regulatory T cells.

Authors:  Ryan J Martinez; Na Zhang; Stephanie R Thomas; Sarada L Nandiwada; Marc K Jenkins; Bryce A Binstadt; Daniel L Mueller
Journal:  J Immunol       Date:  2011-11-28       Impact factor: 5.422

2.  Postmortem diagnosis of chronic granulomatous disease: how worthwhile is it?

Authors:  R Lakshman; S Bruce; D A Spencer; D Crawford; A Galloway; P N Cooper; D Barge; D Roos; T J Flood; M Abinun
Journal:  J Clin Pathol       Date:  2005-12       Impact factor: 3.411

3.  Persistent systemic inflammation and atypical enterocolitis in patients with NEMO syndrome.

Authors:  Laurence E Cheng; Bittoo Kanwar; Haig Tcheurekdjian; James P Grenert; Mica Muskat; Melvin B Heyman; Joseph M McCune; Diane W Wara
Journal:  Clin Immunol       Date:  2009-04-16       Impact factor: 3.969

Review 4.  Inborn errors in immunity: unique natural models to dissect oral immunity.

Authors:  N M Moutsopoulos; M S Lionakis; G Hajishengallis
Journal:  J Dent Res       Date:  2015-04-21       Impact factor: 6.116

5.  Patient-centred screening for primary immunodeficiency: a multi-stage diagnostic protocol designed for non-immunologists.

Authors:  E de Vries
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

6.  N-WASP has the ability to compensate for the loss of WASP in macrophage podosome formation and chemotaxis.

Authors:  Beth M Isaac; Dan Ishihara; Leora M Nusblat; Jean-Claude Gevrey; Athanassios Dovas; John Condeelis; Dianne Cox
Journal:  Exp Cell Res       Date:  2010-06-27       Impact factor: 3.905

7.  Autoimmunity and inflammation in X-linked agammaglobulinemia.

Authors:  Vivian P Hernandez-Trujillo; Chris Scalchunes; Charlotte Cunningham-Rundles; Hans D Ochs; Francisco A Bonilla; Ken Paris; Leman Yel; Kathleen E Sullivan
Journal:  J Clin Immunol       Date:  2014-06-10       Impact factor: 8.317

8.  Host defense pathways: role of redundancy and compensation in infectious disease phenotypes.

Authors:  Simone Nish; Ruslan Medzhitov
Journal:  Immunity       Date:  2011-05-27       Impact factor: 31.745

Review 9.  Autoimmunity in IgA deficiency: revisiting the role of IgA as a silent housekeeper.

Authors:  Cristina M A Jacob; Antonio C Pastorino; Kristine Fahl; Magda Carneiro-Sampaio; Renato C Monteiro
Journal:  J Clin Immunol       Date:  2008-01-17       Impact factor: 8.317

10.  Campylobacter sepsis with multiple organ failure in IgG subclass deficiency.

Authors:  O Kopecký; S Lukesová; J Horácek; R Parízková
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.